Mirxes has announced a strategic investment of $40 million from ARCH Venture Capital's Credit Fund. This funding will propel its rapid growth and expansion into key global markets. The investment employs a medium- to long-term non-dilutive strategy, aimed at accelerating the deployment of its flagship product, GASTROClear™, in the Asia-Pacific region, as well as the clinical validation of other product pipelines.
